193 related articles for article (PubMed ID: 25999236)
1. Reproducibility of mRECIST in assessing response to transarterial radioembolization therapy in hepatocellular carcinoma.
Seyal AR; Gonzalez-Guindalini FD; Arslanoglu A; Harmath CB; Lewandowski RJ; Salem R; Yaghmai V
Hepatology; 2015 Oct; 62(4):1111-21. PubMed ID: 25999236
[TBL] [Abstract][Full Text] [Related]
2. Reproducibility of mRECIST in Measurement and Response Assessment for Hepatocellular Carcinoma Treated by Transarterial Chemoembolization.
Choi MH; Park GE; Oh SN; Park MY; Rha SE; Lee YJ; Jung SE; Choi JI
Acad Radiol; 2018 Nov; 25(11):1363-1373. PubMed ID: 29555570
[TBL] [Abstract][Full Text] [Related]
3. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
[TBL] [Abstract][Full Text] [Related]
4. Alpha-Fetoprotein, Des-Gamma-Carboxy Prothrombin, and Modified RECIST Response as Predictors of Survival after Transarterial Radioembolization for Hepatocellular Carcinoma.
Lim TS; Rhee H; Kim GM; Kim SU; Kim BK; Park JY; Ahn SH; Han KH; Choi JY; Kim DY
J Vasc Interv Radiol; 2019 Aug; 30(8):1194-1200.e1. PubMed ID: 31235408
[TBL] [Abstract][Full Text] [Related]
5. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
Vouche M; Salem R; Lewandowski RJ; Miller FH
Abdom Imaging; 2015 Aug; 40(6):1471-80. PubMed ID: 25412868
[TBL] [Abstract][Full Text] [Related]
6. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria.
Ghosn M; Derbel H; Kharrat R; Oubaya N; Mulé S; Chalaye J; Regnault H; Amaddeo G; Itti E; Luciani A; Kobeiter H; Tacher V
Diagn Interv Imaging; 2021 Jan; 102(1):35-44. PubMed ID: 33012693
[TBL] [Abstract][Full Text] [Related]
7. The Modified Response Evaluation Criteria in Solid Tumors (RECIST) Yield a More Accurate Prognoses Than the RECIST 1.1 in Hepatocellular Carcinoma Treated with Transarterial Radioembolization.
Lee JS; Choi HJ; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Baek SE; Chung YE; Park MS; Kim MJ; Rhee H; Kim SU
Gut Liver; 2020 Nov; 14(6):765-774. PubMed ID: 32050313
[TBL] [Abstract][Full Text] [Related]
8. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
9. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
[No Abstract] [Full Text] [Related]
10. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
Liu Q; Li A; Sun S; Luo R; Chen F
J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
[TBL] [Abstract][Full Text] [Related]
11. Is radioembolization ((90)Y) better than doxorubicin drug eluting beads (DEBDOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis.
Akinwande O; Kim D; Edwards J; Brown R; Philips P; Scoggins C; Martin RC
Surg Oncol; 2015 Sep; 24(3):270-5. PubMed ID: 26133576
[TBL] [Abstract][Full Text] [Related]
12. Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.
Camacho JC; Kokabi N; Xing M; Prajapati HJ; El-Rayes B; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):256-65. PubMed ID: 24461131
[TBL] [Abstract][Full Text] [Related]
13. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602.
Sato Y; Watanabe H; Sone M; Onaya H; Sakamoto N; Osuga K; Takahashi M; Arai Y;
Ups J Med Sci; 2013 Mar; 118(1):16-22. PubMed ID: 23167460
[TBL] [Abstract][Full Text] [Related]
14. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
Liu L; Wang W; Chen H; Zhao Y; Bai W; Yin Z; He C; Jia J; Yang M; Xia J; Fan D; Han G
Clin Cancer Res; 2014 Mar; 20(6):1623-31. PubMed ID: 24493832
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
16. Apparent diffusion coefficient quantification as an early imaging biomarker of response and predictor of survival following yttrium-90 radioembolization for unresectable infiltrative hepatocellular carcinoma with portal vein thrombosis.
Kokabi N; Camacho JC; Xing M; Qiu D; Kitajima H; Mittal PK; Kim HS
Abdom Imaging; 2014 Oct; 39(5):969-78. PubMed ID: 24740759
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Jung ES; Kim JH; Yoon EL; Lee HJ; Lee SJ; Suh SJ; Lee BJ; Seo YS; Yim HJ; Seo TS; Lee CH; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
J Hepatol; 2013 Jun; 58(6):1181-7. PubMed ID: 23395691
[TBL] [Abstract][Full Text] [Related]
18. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
Gillmore R; Stuart S; Kirkwood A; Hameeduddin A; Woodward N; Burroughs AK; Meyer T
J Hepatol; 2011 Dec; 55(6):1309-16. PubMed ID: 21703196
[TBL] [Abstract][Full Text] [Related]
19. US-triggered Microbubble Destruction for Augmenting Hepatocellular Carcinoma Response to Transarterial Radioembolization: A Randomized Pilot Clinical Trial.
Eisenbrey JR; Forsberg F; Wessner CE; Delaney LJ; Bradigan K; Gummadi S; Tantawi M; Lyshchik A; O'Kane P; Liu JB; Intenzo C; Civan J; Maley W; Keith SW; Anton K; Tan A; Smolock A; Shamimi-Noori S; Shaw CM
Radiology; 2021 Feb; 298(2):450-457. PubMed ID: 33320067
[TBL] [Abstract][Full Text] [Related]
20. MDCT necrosis quantification in the assessment of hepatocellular carcinoma response to yttrium 90 radioembolization therapy: comparison of two-dimensional and volumetric techniques.
Galizia MS; Töre HG; Chalian H; McCarthy R; Salem R; Yaghmai V
Acad Radiol; 2012 Jan; 19(1):48-54. PubMed ID: 22054801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
